Burke Therapeutics has signed an exclusive marketing and supply agreement with Coeptis Pharmaceuticals for the U.S. market. Burke will market the fixed-dose combination drug, Consensi®, a prescription medicine for adults who need both treatment with amlodipine for hypertension, to lower blood pressure, and celecoxib for the management of the signs and symptoms of osteoarthritis. Commercial launch is anticipated in May of 2020.
Consensi is a fixed-dose combination of amlodipine besylate, a calcium channel blocker for the treatment of hypertension, to lower blood pressure, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) for the management of the signs and symptoms of osteoarthritis. The U.S. Food & Drug Administration (FDA) approved Consensi oral tablets for marketing on May 31, 2018.